On its own, the potential of IMV Inc.’s (IMV Stock Quote, Chart TSX:IMV) cancer-fighting drug DPX-Survivac is encouraging, but the just-released news … [Read more...] about IMV has 45 per cent upside, Echelon says
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Tetra Bio-Pharma financing a “sea-change” for the company, Paradigm Capital says
A new financing for Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart: TSXV:TBP) has Paradigm Capital analyst Rahul Sarugaser maintaining his … [Read more...] about Tetra Bio-Pharma financing a “sea-change” for the company, Paradigm Capital says
Bellus Health has 132 per cent upside, Mackie Research says
Clinical-stage drug company Bellus Health (Bellus Health Stock Quote, Chart: TSX:BLU) is developing a potentially best-in-class chronic cough drug, … [Read more...] about Bellus Health has 132 per cent upside, Mackie Research says
ProMetic Life Sciences still has financial risk, Echelon Wealth Partners says
Biopharm company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) announced its third quarter 2018 financials this week, but … [Read more...] about ProMetic Life Sciences still has financial risk, Echelon Wealth Partners says
Oncolytics Biotech has 228 per cent upside, Echelon says
Oncolytics Biotech (Oncolytics Biotech Stock Quote, Chart TSX:ONC) announced its third quarter financials on Monday, with the Calgary-based cancer … [Read more...] about Oncolytics Biotech has 228 per cent upside, Echelon says
Acasti Pharma has a potential blockbuster drug on its hands, Mackie Research says
Results from a recent study of an omega-3 drug used to treat cardiovascular disease should increase prescriptions of OMG3s in the US, says Mackie … [Read more...] about Acasti Pharma has a potential blockbuster drug on its hands, Mackie Research says
2019 will be Profound Medical’s breakout year, Paradigm Capital says
In a research note to clients on Friday, Paradigm Capital’s Rahul Sarugaser laid out the argument for why investors should view 2019 as Profound … [Read more...] about 2019 will be Profound Medical’s breakout year, Paradigm Capital says
Acerus Pharmaceuticals has huge upside, Mackie Research says
Specialty pharma company Acerus Pharmaceuticals (TSX:ASP) produced soft results in its third quarter, according to analyst André Uddin of Mackie … [Read more...] about Acerus Pharmaceuticals has huge upside, Mackie Research says
Tetra Bio-Pharma acquisition of Panag Pharma gets thumbs up at Paradigm
A new acquisition for Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart: TSX:TBP) turns the company into a vertically integrated pharma company, … [Read more...] about Tetra Bio-Pharma acquisition of Panag Pharma gets thumbs up at Paradigm
Acerus Pharma’s C-suite shakeup is a positive, Mackie Research says
Specialty pharma company Acerus Pharmaceuticals (Acerus Pharmaceuticals Stock Quote, Chart TSX:ASP) has announced a changeup in the CFO role effective … [Read more...] about Acerus Pharma’s C-suite shakeup is a positive, Mackie Research says